By Denise R. Aberle, MD The seminal National Lung Screening Trial (NLST) showed that lung cancer screening using low dose computed tomography (LDCT) resulted in a 20% decrease in lung […] Read more
By Peter Ujhazy, MD, PhD The newfound optimism in the management of lung cancer that infused the research, clinical, and patient communities 12 years ago is still gaining momentum. Seminal […] Read more
By Erik J. MacLaren, PhD This year’s annual meeting of the American Society of Clinical Oncology (ASCO) is taking place June 3–7 in Chicago. The theme of the meeting this […] Read more
By Erik J. MacLaren, PhD Immunotherapy with anti-PD-L1/PD-1 antibodies is rapidly changing the therapeutic landscape for patients with non-small cell lung cancer (NSCLC). However, selecting the most optimal patient population […] Read more
By Gerard A. Silvestri, MD, MS, FCCP A recent population-based study suggested the incidence of pulmonary nodules detected by CT is around 1.5 million per year. This finding is no […] Read more
By James L. Mulshine, MD, PhD, Fred Hirsch, MD, PhD, and John K. Field, PhD, FRCPath Over the last fifteen years, the use of lowdose computed tomography (LDCT) for early […] Read more
By Nicola M. Parry, DVM From May 13 to 15, 2016, the 7th International Association for the Study of Lung Cancer (IASLC) Asia Pacific Lung Cancer Conference (APLCC) took place […] Read more
By: Corey J. Langer, MD, FACP Professor of Medicine University of Pennsylvania Editor, IASLC Lung Cancer News Welcome to the second issue of IASLC Lung Cancer News. In concert with the […] Read more
By Prof. Fabien Calvo, MD, PhD Today, cancer research is facing several challenges. The genomics era has ushered in a host of new molecular therapies; however, most of these targeted […] Read more
Dear Colleagues, We are inviting you to take part in the IASLC 17th World Conference on Lung Cancer in Vienna, December 4-7, 2016. This Conference will be the first of […] Read more